Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307917 | 0.68 | HSP90AB1 (0.46) | HSP90AB1CYP2C19HSP90AA1HRH4CYP2C9 | |
| SCHEMBL6308795 | 0.68 | HSP90AB1 (0.42) | HSP90AB1HSP90AA1 | |
| SCHEMBL6314269 | 0.66 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1HSP90AA1HRH3 | |
| SCHEMBL6307180 | 0.66 | HSP90AA1 (0.57) | HSP90AB1HSP90AA1 | |
| SCHEMBL6314302 | 0.65 | HSP90AA1 (0.41) | HSP90AB1L3MBTL1CYP2D6ALDH1A1HSP90AA1 | |
| SCHEMBL8071682 | 0.64 | HSP90AB1 (0.71) | HSP90AB1HSP90AA1 | |
| SCHEMBL3631158 | 0.64 | HSP90AB1 (0.71) | HSP90AB1HSP90AA1 | |
| SCHEMBL6308343 | 0.64 | HSP90AB1 (0.48) | HSP90AB1ALDH1A1HSP90AA1 | |
| SCHEMBL19917182 | 0.63 | ABCB1 (0.32) | — | |
| SCHEMBL10897011 | 0.63 | MEN1 (0.47) | HSP90AB1CYP2C19HSP90AA1HRH4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | HSP90AB1 1191/4885L3MBTL1 915/4885CYP2D6 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.